We have developed vector-producing tumor-targeting cells by using stem cells that have the ability to accumulate in tumors. The cells are administered systemically and accumulate at cancer sites where they express the therapeutic gene, which is expected to result in enhanced efficacy against invasive and metastatic lesions where conventional anticancer drug or radiation therapies are ineffective.